Literature DB >> 23321165

Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma.

J Yuan1, L Chen, X Chen, W Sun, X Zhou.   

Abstract

OBJECTIVE: The aim of this study was to investigate the serum level of microRNA (miR)-21 in patients with osteosarcoma and its correlation with chemosensitivity and prognosis.
METHODS: miR-21 levels in sera from 65 patients with osteosarcoma and 30 healthy controls were measured by real-time reverse transcription-polymerase chain reaction. Correlations between serum miR-21 and clinicopathological features in patients with osteosarcoma were determined. The prognostic significance of serum miR-21 was assessed using a Cox proportional hazards model.
RESULTS: The serum level of miR-21 was significantly higher in patients with osteosarcoma than in control subjects. High serum miR-21 was significantly correlated with advanced Enneking stage and chemotherapeutic resistance. Univariate and multivariate analyses for overall survival showed that upregulation of serum miR-21 was an independent, unfavourable prognostic factor for patients with osteosarcoma (hazard ratio, 2.325).
CONCLUSIONS: miR-21 might be a good candidate for a therapeutic target, and a potential biomarker for the prediction of chemotherapeutic sensitivity and prognosis in patients with osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23321165     DOI: 10.1177/030006051204000606

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  31 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

3.  miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.

Authors:  Shuguang Zhou; Bing Wang; Jun Hu; Yucheng Zhou; Mengzhen Jiang; Mingyu Wu; Liming Qin; Xuming Yang
Journal:  Tumour Biol       Date:  2016-01-13

4.  Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.

Authors:  Chun Zhang; Cong Yao; Haopeng Li; Guoyu Wang; Xijing He
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.

Authors:  Yisila Mu; Haoshaqiang Zhang; Lixin Che; Kun Li
Journal:  Med Oncol       Date:  2013-12-19       Impact factor: 3.064

6.  Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcoma.

Authors:  Nai-Guo Wang; Da-Chuan Wang; Bing-Yi Tan; Feng Wang; Ze-Nong Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

7.  Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

Review 8.  Role of microRNAs in primary central nervous system lymphomas.

Authors:  Xin Yu; Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-03-16       Impact factor: 6.831

9.  Limb versus life: the outcomes of osteosarcoma in Cambodia.

Authors:  Saqib Noor; Hjörleifur Skorri Thornormóðsson; Colin Thomas Zervas; Tho Ly; James Gollogly
Journal:  Int Orthop       Date:  2013-12-05       Impact factor: 3.075

10.  Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis.

Authors:  Yinlong Yang; Jinxian Qian; Yizuo Chen; Yifei Pan
Journal:  Tumour Biol       Date:  2014-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.